Skip to main content
. Author manuscript; available in PMC: 2021 Aug 6.
Published in final edited form as: J Am Coll Cardiol. 2019 Mar 17;74(10):1376–1414. doi: 10.1016/j.jacc.2019.03.009

FIGURE 2. Treatment of T2DM for Primary Prevention of Cardiovascular Disease.

FIGURE 2

CVD indicates cardiovascular disease; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, hemoglobin A1c; SGLT-2, sodium-glucose cotransporter 2; and T2DM, type 2 diabetes mellitus.